FRI0470 Comparative Study of Infliximab versus Adalimumab in Patients with Refractory Uveitis Due to BehÇEt's Disease. Multicenter Study of 125 Cases. (10th June 2014)

• Record Type: Journal Article
• Authors: Beltrán-Catalán, E.; Calvo-Río, V.; Rodríguez-Cundin, P.; Blanco-Alonso, R.; Sánchez-Bursόn, J.; Mesquida, M.; Adán, A.; Hernandez, M.V.; Hernandez Garfella, M.; Martínez-Costa, L.; Sellas, A.; Cordero Coma, M.; Díaz-Llopis, M.; García Serrano, J.L.; Ortego, N.; Herreras, J.M.; Fonollosa, A.; García-Aparicio, Ά.M.; Maíz, O.; Blanco, A.; Torre, I.; Fernández-Espartero, C.; Jovaní, V.; Peiteado, D.; Pato-Cour, E.; Cruz, J.; Aurrecoechea, E.; García, M.; Caracuel, M.A.; Montilla, C.; Atanes, A.; Francisco, F.; González, S.; González-Gay, M.A.;
• Is Part Of: Annals of the rheumatic diseases. Volume 73:Supplement 2(2014)
• Page Start: 557
• Page End: 557
• Publication Date: 2014-06-10
• Subjects: Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/annrheumdis-2014-eular.4766
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : Objectives: To compare the efficacy and safety of infliximab (IFX) versus adalimumab (ADA) as first biologic drug in refractory uveitis due to Behçet's disease (BD) for 1-year period. Methods: Multicenter study of 125 patients with BD's uveitis refractory to conventional treatment including high-dose corticosteroids and at least one standard immunosuppressive agent. IFX (3-5 mg/kg at 0, 2, and 6 weeks and then every 4-8 weeks) was used in 75 cases and ADA (usually 40 mg every 2 weeks) in 50 cases. The main comparative outcome measures were improvement of visual acuity (VA) (at least 20%), complete inactivity of anterior chamber inflammation, vitritis, and retinal vasculitis as well as macular thickness <250 microns. A bivariate and logistic regression analysis was performed for every previous outcome between ADA vs IFX (SPSS20.0 package). Results: 125 patients (223 affected eyes) were studied. No statistically significant differences at baseline were observed between IFX vs ADA groups in sex (♂/♀; 41/34 vs 29/21; p=0, 71), mean age (39, 2±9.39 vs 36, 14±12, 7; p=0.12), HLA B51 positive (75% vs 75%), uveitis duration before anti TNF-α onset (median [IQR]; 36 [12-71] vs 24 months [12-60]; p=0.4), VA (0, 47±0, 26 vs 0, 52±0, 27; p=0, 29), anterior chamber cells (median [IQR]; 0, 5 [0-2] vs 1, 5 [0-2]; p=0, 2), retinal vasculitis (73, 2% vs 75%; p=0, 95); macular thickness (285, 90±90, 15 vs 312, 02±106, 57; p=0, 25), combined treatment (82.7% vs 77, 6%; p=0.481), basal degrees of immunosuppression (mean ± SD; 11.35±5.67 vs 9.65±4.68; p=0.09). There were a better non-statistical respond with ADA in improvement of VA, complete inactivity of anterior chamber inflammation, and macular thickness <250 microns, and with IFX in inactivity of vitritis, and retinal vasculitis (Table) Conclusions: Our study suggests that ADA and IFX do not show statistical differences at one year in refractory uveitis of BD. Disclosure of Interest: None declared DOI: 10.1136/annrheumdis-2014-eular.4766